Previous 10 | Next 10 |
While the broader market is still in the red for the year, it has performed decently in the past three months with the S&P 500 rising by almost 8% in this period. Could this be the start of a new bull market? It's too early to tell. Many companies that have performed even better rec...
Only blood test that detects minimal residual disease in patients with solid tumors without need for tissue biopsy now available for three cancers impacting 6 million people in US annually 1 Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, announc...
The U.S. Food and Drug Administration (FDA) approved Guardant Health's ( NASDAQ: GH ) liquid biopsy test Guardant360 CDx as a companion diagnostic (CDx) to select patients for the new use of AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo's ( OTCPK:DSKYF...
Blood test provides simple way to test patients comprehensively for tumor alterations that drive selection of targeted therapies, now including ENHERTU Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Admin...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point, CA. Guardant Health’s management is scheduled to participate in a fires...
Friday was a good day to be a Guardant Health (NASDAQ: GH) shareholder. Thanks to an encouraging second-quarter report after market close on Thursday, investors embraced the oncology diagnostics specialist, buying into it enough to send the share price to a gain of almost 4%, in con...
Presentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific mutations on treatment efficacy, and informing therapeutic strategies in lung cancer Guardant Health, Inc. (Nasdaq: GH...
Guardant Health, Inc. (GH) Q2 2022 Earnings Conference Call August 04, 2022 04:30 PM ET Company Participants Alex Kleban - Vice President, Investor Relations Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - ...
The following slide deck was published by Guardant Health, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Guardant Health, Inc. 2022 Q2 - Results - Earnings Call Presentation
Guardant Health press release ( NASDAQ: GH ): Q2 Non-GAAP EPS of -$1.00 misses by $0.03 . Revenue of $109.1M (+18.5% Y/Y) beats by $3.96M . Guardant Health continues to expect full year 2022 revenue to be in the range of $460 million to $470 million vs. $465.73...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...